ArticleSurgical endoscopy2025
Role of radiofrequency STRETTA for recurrent GERD following primary anti-reflux surgery and primary STRETTA therapy.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastroesophageal reflux disease (GERD) is a common chronic condition affecting millions all over the world. It occurs due to the reflux of gastric acid into the oesophagus. Endoscopic therapies like STRETTA offer minimally invasive options to manage GERD. This study aims to evaluate the role of STRETTA in patients with recurrent symptoms after structurally intact hiatus hernia repair with anti-reflux surgery (ARS) and in patients who had an initially successful STRETTA.
methodsA retrospective review was conducted on patients who underwent STRETTA from 2014 to 2024 at a tertiary centre to identify patients whose STRETTA therapy followed either a primary ARS (OP to STR) or primary STRETTA (STR to STR). Patients' outcomes were assessed before and after the STRETTA procedure using validated RSI (Reflux symptom index), and GERD HRQL (Gastro Esophageal Reflux Disease Health-Related Quality of Life) quality of life (QoL) questionnaires. The use of anti-secretory medications was analysed using Chi-Square (X
results19 eligible patients were studied under 2 cohorts: 13 underwent STRETTA following a primary ARS (OP to STR) and 6 had a repeat STRETTA following a primary successful STRETTA (STR to STR). The median time from ARS to STRETTA was 8.7 years compared with 5.5 years in the STR to STR group, p = 0.180. The median follow-up in the ARS to STR group was significantly longer at 5.7 years compared to 0.8 years in the STR to STR, p = 0.008. The median age was 66.0 years in ARS to STRETTA group and 54.5 years in the STR to STR cohort. The OP to STR cohort saw a significant reduction in the RSI (Wilcoxon V = 84.5, p = 0.007) and improvement in QoL (Wilcoxon V = 66, p = 0.004). The STR to STR cohort did not show a statistically significant improvement in either RSI (Wilcoxon V = 15, p = 0.058) or QoL scores (Wilcoxon V = 19, p = 0.093). No statistically significant difference was noted in the usage of PPIs in either cohort.
conclusionThis retrospective, small sample and single-centre study opens the debate about the role of endoscopic radiofrequency STRETTA therapy in selected recurrent GERD patients following successful primary ARS. Furthermore, though our limited data showed no statistically significant benefit in RSI and GERD HRQL for the STR to STR cohort, this is a compelling topic which begs for larger robust studies.
Indexed as
Identifiers
40425859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.